Download this Paper Open PDF in Browser

Adverse Drug Reactions: Harnessing Experiential Data to Promote Patient Welfare

56 Pages Posted: 12 Jan 2012 Last revised: 17 Jan 2012

Barbara A. Noah

Western New England University School of Law

Date Written: 2000

Abstract

Part I of this Article evaluates the pre-approval and post-approval regulatory framework governing prescription drugs, and the FDA's spontaneous reporting system for adverse events, as it contrasts that system with the regulatory mechanisms used to monitor risks associated with other products. Part II summarizes the recent series of prescription drug marketing withdrawals prompted by reports of unexpected adverse reactions. Finally, Part III offers some possible solutions designed to improve the efficiency of post-approval surveillance so that fewer patients will suffer the consequences of unexpected adverse drug reactions and interactions. This Article concludes that the existing regulatory system requires fundamental reprioritization and more substantial structural reforms in order to avoid a troubling replay of recent prescription drug withdrawals. The proposed reforms may help to enhance a physician's ability to provide quality patient care based on optimal knowledge of the safety and efficacy of pharmaceutical products.

Keywords: adverse drug reactions, health law, food and drug law, health law

Suggested Citation

Noah, Barbara A., Adverse Drug Reactions: Harnessing Experiential Data to Promote Patient Welfare (2000). Catholic University Law Review, Vol. 49, p. 449, 2000. Available at SSRN: https://ssrn.com/abstract=1983449

Barbara A. Noah (Contact Author)

Western New England University School of Law ( email )

1215 Wilbraham Road
Springfield, MA 01119
United States
413-782-1432 (Phone)

Paper statistics

Downloads
20
Abstract Views
307